Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 666 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Making real change: 4 ways we’ve influenced cancer policy July 6, 2022 Neoadjuvant Chemotherapy with mFOLFIRINOX Followed by Chemoradiotherapy Improves Survival in Patients... August 14, 2024 FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs... October 16, 2025 FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone... November 27, 2020 Load more HOT NEWS Virtual Reality Found to Benefit Cancer Patients’ Mental Health Autumn and Letting Go Workout Wednesdays – Chest Exercises Part 1 Your Microbiome and Cancer: What to Know
